Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: Evaluation of blood pNF-H as a potential ALS biomarker

Kevin Boylan, Cui Yang, Juliana Crook, Karen Overstreet, Michael Heckman, Yong Wang, David Borchelt, Gerry Shaw

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Levels of neurofilament subunits, potential biomarkers of motor axon breakdown, are increased in amyotrophic lateral sclerosis (ALS) patient's CSF but data on blood are not available. We measured blood levels of the phosphorylated axonal form of neurofilament H (pNF-H) by ELISA in transgenic rodent models of superoxide dismutase 1 (SOD1) ALS, and in 20 ALS patients and 20 similar aged controls monthly for 4 months. All symptomatic rodent ALS models showed robust levels of blood pNF-H, while control rodents or mice transgenic for unmutated SOD1 showed no detectable blood pNF-H. Average pNF-H levels in the G93A SOD1 mouse progressively increased from day 74 through death (day ∼130). Median blood pNF-H level in ALS patients was 2.8-fold higher than controls (p < 0.001). Median ALSFRS-R declined a median of 0.8 pt/month (p < 0.001); higher baseline pNF-H level appeared to be associated with faster ALSFRS-R decline over 4 months (p = 0.087). The median rate of decline in ALSFRS-R was 1.9 pt/month in patients with baseline pNF-H levels above the median pNF-H value of 0.53 ng/mL; ALSFRS-R declined at a median of 0.6 pt/month in patients below this level. The pNF-H levels were relatively stable month to month in individual patients, raising questions regarding the molecular pathogenesis of ALS. Baseline control human pNF-H levels were higher in men than women and increased minimally over time. These data suggest that blood pNF-H can be used to monitor axonal degeneration in ALS model rodents and support further study of this protein as a potential biomarker of disease prognosis in ALS patients.

Original languageEnglish (US)
Pages (from-to)1182-1191
Number of pages10
JournalJournal of Neurochemistry
Volume111
Issue number5
DOIs
StatePublished - Dec 2009

Fingerprint

Intermediate Filaments
Amyotrophic Lateral Sclerosis
Biomarkers
Rodentia
Blood
Superoxide Dismutase
Rodent Control
Transgenic Mice
Axons
Enzyme-Linked Immunosorbent Assay
Proteins

Keywords

  • Amyotrophic lateral sclerosis
  • Biomarker
  • Neurofilament
  • Phosphorylated axonal neurofilament H subunit
  • Superoxide dismutase 1
  • Transgenic rodents

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients : Evaluation of blood pNF-H as a potential ALS biomarker. / Boylan, Kevin; Yang, Cui; Crook, Juliana; Overstreet, Karen; Heckman, Michael; Wang, Yong; Borchelt, David; Shaw, Gerry.

In: Journal of Neurochemistry, Vol. 111, No. 5, 12.2009, p. 1182-1191.

Research output: Contribution to journalArticle

Boylan, Kevin ; Yang, Cui ; Crook, Juliana ; Overstreet, Karen ; Heckman, Michael ; Wang, Yong ; Borchelt, David ; Shaw, Gerry. / Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients : Evaluation of blood pNF-H as a potential ALS biomarker. In: Journal of Neurochemistry. 2009 ; Vol. 111, No. 5. pp. 1182-1191.
@article{ae5e162b0480469697b517dad1239592,
title = "Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: Evaluation of blood pNF-H as a potential ALS biomarker",
abstract = "Levels of neurofilament subunits, potential biomarkers of motor axon breakdown, are increased in amyotrophic lateral sclerosis (ALS) patient's CSF but data on blood are not available. We measured blood levels of the phosphorylated axonal form of neurofilament H (pNF-H) by ELISA in transgenic rodent models of superoxide dismutase 1 (SOD1) ALS, and in 20 ALS patients and 20 similar aged controls monthly for 4 months. All symptomatic rodent ALS models showed robust levels of blood pNF-H, while control rodents or mice transgenic for unmutated SOD1 showed no detectable blood pNF-H. Average pNF-H levels in the G93A SOD1 mouse progressively increased from day 74 through death (day ∼130). Median blood pNF-H level in ALS patients was 2.8-fold higher than controls (p < 0.001). Median ALSFRS-R declined a median of 0.8 pt/month (p < 0.001); higher baseline pNF-H level appeared to be associated with faster ALSFRS-R decline over 4 months (p = 0.087). The median rate of decline in ALSFRS-R was 1.9 pt/month in patients with baseline pNF-H levels above the median pNF-H value of 0.53 ng/mL; ALSFRS-R declined at a median of 0.6 pt/month in patients below this level. The pNF-H levels were relatively stable month to month in individual patients, raising questions regarding the molecular pathogenesis of ALS. Baseline control human pNF-H levels were higher in men than women and increased minimally over time. These data suggest that blood pNF-H can be used to monitor axonal degeneration in ALS model rodents and support further study of this protein as a potential biomarker of disease prognosis in ALS patients.",
keywords = "Amyotrophic lateral sclerosis, Biomarker, Neurofilament, Phosphorylated axonal neurofilament H subunit, Superoxide dismutase 1, Transgenic rodents",
author = "Kevin Boylan and Cui Yang and Juliana Crook and Karen Overstreet and Michael Heckman and Yong Wang and David Borchelt and Gerry Shaw",
year = "2009",
month = "12",
doi = "10.1111/j.1471-4159.2009.06386.x",
language = "English (US)",
volume = "111",
pages = "1182--1191",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients

T2 - Evaluation of blood pNF-H as a potential ALS biomarker

AU - Boylan, Kevin

AU - Yang, Cui

AU - Crook, Juliana

AU - Overstreet, Karen

AU - Heckman, Michael

AU - Wang, Yong

AU - Borchelt, David

AU - Shaw, Gerry

PY - 2009/12

Y1 - 2009/12

N2 - Levels of neurofilament subunits, potential biomarkers of motor axon breakdown, are increased in amyotrophic lateral sclerosis (ALS) patient's CSF but data on blood are not available. We measured blood levels of the phosphorylated axonal form of neurofilament H (pNF-H) by ELISA in transgenic rodent models of superoxide dismutase 1 (SOD1) ALS, and in 20 ALS patients and 20 similar aged controls monthly for 4 months. All symptomatic rodent ALS models showed robust levels of blood pNF-H, while control rodents or mice transgenic for unmutated SOD1 showed no detectable blood pNF-H. Average pNF-H levels in the G93A SOD1 mouse progressively increased from day 74 through death (day ∼130). Median blood pNF-H level in ALS patients was 2.8-fold higher than controls (p < 0.001). Median ALSFRS-R declined a median of 0.8 pt/month (p < 0.001); higher baseline pNF-H level appeared to be associated with faster ALSFRS-R decline over 4 months (p = 0.087). The median rate of decline in ALSFRS-R was 1.9 pt/month in patients with baseline pNF-H levels above the median pNF-H value of 0.53 ng/mL; ALSFRS-R declined at a median of 0.6 pt/month in patients below this level. The pNF-H levels were relatively stable month to month in individual patients, raising questions regarding the molecular pathogenesis of ALS. Baseline control human pNF-H levels were higher in men than women and increased minimally over time. These data suggest that blood pNF-H can be used to monitor axonal degeneration in ALS model rodents and support further study of this protein as a potential biomarker of disease prognosis in ALS patients.

AB - Levels of neurofilament subunits, potential biomarkers of motor axon breakdown, are increased in amyotrophic lateral sclerosis (ALS) patient's CSF but data on blood are not available. We measured blood levels of the phosphorylated axonal form of neurofilament H (pNF-H) by ELISA in transgenic rodent models of superoxide dismutase 1 (SOD1) ALS, and in 20 ALS patients and 20 similar aged controls monthly for 4 months. All symptomatic rodent ALS models showed robust levels of blood pNF-H, while control rodents or mice transgenic for unmutated SOD1 showed no detectable blood pNF-H. Average pNF-H levels in the G93A SOD1 mouse progressively increased from day 74 through death (day ∼130). Median blood pNF-H level in ALS patients was 2.8-fold higher than controls (p < 0.001). Median ALSFRS-R declined a median of 0.8 pt/month (p < 0.001); higher baseline pNF-H level appeared to be associated with faster ALSFRS-R decline over 4 months (p = 0.087). The median rate of decline in ALSFRS-R was 1.9 pt/month in patients with baseline pNF-H levels above the median pNF-H value of 0.53 ng/mL; ALSFRS-R declined at a median of 0.6 pt/month in patients below this level. The pNF-H levels were relatively stable month to month in individual patients, raising questions regarding the molecular pathogenesis of ALS. Baseline control human pNF-H levels were higher in men than women and increased minimally over time. These data suggest that blood pNF-H can be used to monitor axonal degeneration in ALS model rodents and support further study of this protein as a potential biomarker of disease prognosis in ALS patients.

KW - Amyotrophic lateral sclerosis

KW - Biomarker

KW - Neurofilament

KW - Phosphorylated axonal neurofilament H subunit

KW - Superoxide dismutase 1

KW - Transgenic rodents

UR - http://www.scopus.com/inward/record.url?scp=70350782376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350782376&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2009.06386.x

DO - 10.1111/j.1471-4159.2009.06386.x

M3 - Article

C2 - 19765193

AN - SCOPUS:70350782376

VL - 111

SP - 1182

EP - 1191

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 5

ER -